TERMS OF USE

By downloading the materials made available to you on the Association for Professionals in Infection Control and Epidemiology, Inc. (“APIC”) website (“APIC Materials”), you acknowledge that you have read and agree to be bound by these Terms of Use. The copyright in all APIC Materials are owned by APIC and all rights are reserved. The APIC Materials are being made available for download free of charge for the limited purpose of educating healthcare professionals. By making the APIC Materials available for download, APIC is not granting any right of ownership; rather, APIC is providing you with a limited license to use the materials for limited purpose and in limited ways. APIC may cease making the APIC Materials available at any time and for any reason.

- EDUCATIONAL USE ONLY: You agree that your download and use of the APIC Materials is for educational use only. Any copies made of the APIC Materials may only be for educational use. Copies may not be made for any other purpose whatsoever. All copies must contain the copyright notice as it appears on the APIC Materials, namely “© 2014 Association for Professionals in Infection Control and Epidemiology, Inc. All Rights Reserved.”
- NO COMMERCIAL USE: You agree not to reproduce, duplicate, copy, sell, trade, resell or exploit for any commercial purposes, any portion or use of, or access to, the APIC Materials.
- NO POSTING; ONLY LINKING: You may not post the APIC Materials elsewhere, including on social media, blogs, or other websites. However, we welcome you to provide a link to the APIC website where the APIC Materials may be found. You may not engage in framing or inline linking of the APIC Materials.
- NO ALTERATION, EXCERPTING, DERIVATION: You may not alter the APIC Materials in any way, including by excerpting. You may not create derivative works from the APIC Materials.

The Association for Professionals in Infection Control and Epidemiology, its affiliates, directors, officers, and/or agents (collectively, “APIC and Agents”) provides this APIC Text solely for the purpose of providing information to APIC members and the general public. The material presented in the APIC Materials has been prepared in good faith with the goal of providing accurate and authoritative information regarding the subject matter covered. However, APIC and Agents makes no representation or warranty of any kind regarding any information, apparatus, product, or process discussed in the APIC Materials and any linked or referenced materials contained therein, and APIC and agents assumes no liability therefore.

WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, THE INFORMATION AND MATERIALS PROVIDED IN THE APIC MATERIALS ARE PROVIDED ON AN “AS-IS” BASIS AND MAY INCLUDE ERRORS, OMISSIONS, OR OTHER INACCURACIES. THE USER ASSUMES THE SOLE RISK OF MAKING USE AND/OR RELYING ON THE INFORMATION AND MATERIALS PROVIDED IN THE APIC MATERIALS. APIC AND AGENTS MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE SUITABILITY, COMPLETENESS, TIMELINESS, RELIABILITY, LEGALITY, UTILITY OR ACCURACY OF THE INFORMATION AND MATERIALS PROVIDED IN THE APIC
MATERIALS OR ANY PRODUCTS, SERVICES, AND TECHNIQUES DESCRIBED IN THE APIC MATERIALS. ALL SUCH INFORMATION AND MATERIALS ARE PROVIDED WITHOUT WARRANTY OF ANY KIND, INCLUDING, WITHOUT LIMITATION, ALL IMPLIED WARRANTIES AND CONDITIONS OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE, AND NON-INFRINGEMENT.

IN NO EVENT SHALL APIC AND AGENTS BE LIABLE FOR ANY INDIRECT, PUNITIVE, INCIDENTAL, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE USE OF THE APIC MATERIALS OR FOR THE USE OF ANY PRODUCTS, SERVICES, OR TECHNIQUES DESCRIBED IN THE APIC MATERIALS, WHETHER BASED IN CONTRACT, TORT, STRICT LIABILITY, OR OTHERWISE.
# TABLE OF CONTENTS

## VOLUME I

**Acknowledgements**  
Editors  
Authors  
Reviewers  
Production Staff  
Declarations of Conflicts of Interest  
Preface

### Section 1. Overview of Infection Prevention Programs

1. Infection Prevention and Control Programs  
2. Competency and Certification of the Infection Preventionist  
3. Education and Training  
4. Accrediting and Regulatory Agencies  
5. Infection Prevention and Behavioral Interventions  
6. Healthcare Informatics and Information Technology  
7. Product Evaluation  
8. Legal Issues  
9. Staffing

### Section 2. Epidemiology, Surveillance, Performance, and Patient Safety Measures

10. General Principles of Epidemiology  
11. Surveillance  
12. Outbreak Investigations  
13. Use of Statistics in Infection Prevention  
14. Process Control Charts  
15. Risk-adjusted Comparisons  
16. Quality Concepts  
17. Performance Measures  
18. Patient Safety  
19. Qualitative Research Methods  
20. Research Study Design

### Section 3. Microbiology and Risk Factors for Transmission

21. Risk Factors Facilitating Transmission of Infectious Agents  
22. Microbial Pathogenicity and Host Response  
23. The Immunocompromised Host  
24. Microbiology Basics  
25. Laboratory Testing and Diagnostics  
26. Antimicrobials and Resistance

## VOLUME II

### Section 4. Basic Principles of Infection Prevention Practice

27. Hand Hygiene  
28. Standard Precautions  
29. Isolation Precautions (Transmission-based Precautions)  
30. Aseptic Technique  
31. Cleaning, Disinfection, and Sterilization  
32. Reprocessing Single-use Devices

### Section 5. Prevention Measures for Healthcare-Associated Infections

33. Urinary Tract Infection  
34. Intravascular Device Infections  
35. Infections in Indwelling Medical Devices  
36. Pneumonia  
37. Surgical Site Infection

### Section 6. Infection Prevention for Specialty Care Populations

38. Burns  
39. Dialysis  
40. Geriatrics  
41. Neonates  
42. Pediatrics  
43. Perinatal Care  
44. Infection Prevention in Oncology and Other Immunocompromised Patients  
45. Solid Organ Transplantation  
46. Hematopoietic Stem Cell Transplantation  
47. Nutrition and Immune Function

### Section 7. Infection Prevention for Practice Settings and Service-Specific Patient Care Areas

48. Ambulatory Care  
49. Behavioral Health  
50. Cardiac Catheterization and Electrophysiology  
51. Correctional Facilities  
52. Child Care Services  
53. Dental Services  
54. Emergency and Other Pre-Hospital Medical Services  
55. Endoscopy
Preface

When I was asked to be the clinical editor for the 4th edition of the APIC Text of Infection Control and Epidemiology, I could not imagine a greater honor nor could I imagine a greater challenge! After more than 25 years of a very active infection prevention practice, I was being offered this great opportunity to lead the revision of the most prominent infection prevention and control reference book. When I accepted this offer, I began to sense that this opportunity was not as much a call to lead, as it was a call to serve—a call to serve the APIC organization, as well as you the consumer of the APIC Text. Admittedly, in some ways the task ahead was intimidating as I realized that the consumer would be you, the infection preventionist, each with your own knowledge and experiences—your own expertise.

Although the work has been challenging, the rewards have been much greater. I have had the opportunity to work with 12 accomplished, committed section editors and more than 150 authors—all leaders and experts in infection prevention. They have all worked diligently to produce a quality reference to help you make informed, effective, and timely decisions in your infection prevention program.

Let me share a few points about the 4th edition. All the chapters have been revised and updated to reflect current practices and guidelines at the time of publication. Because much of healthcare is rapidly moving outside the acute care setting, particular attention has been focused on infection prevention practices in alternative healthcare settings such as rehabilitation, ambulatory care centers and long-term acute care settings. In fact, four new chapters have been added to address current trends and issues: Chapter 2 Competency and Certification of the Infection Preventionist, Chapter 28 Standard Precautions, Chapter 62 Long-Term Acute Care, and Chapter 64 Ambulatory Surgery Centers.

The 4th edition of the APIC Text is printed in three volumes to make reading and handling easier, and the chapters have been arranged into sections so that information on programs or specialty areas, for example, are presented together. Additionally, each chapter contains international perspectives and future trends.

As you open the pages of the APIC Text, 4th edition, you will find within its contents the most up-to-date information to meet your everyday needs in the work setting. Infection preventionists now more than ever have a major role in the protection and safety of healthcare personnel and patients in both traditional, as well as nontraditional settings. Having access to the Text—whether in hard copy or electronically via the APIC Text Online—is essential to your practice. It has been my pleasure to work for you in order to publish the newest edition of the APIC Text.

Finally, I would be remiss if I did not acknowledge the efforts of those who built the foundation for this fourth edition. Without them, especially Dr. Ruth Carrico, who served as the editor of the first three editions of the APIC Text, this work could not have been as comprehensive, and of the quality, it is.

Regards,

Patti G. Grota, PhD, RN, CNS-M-S, CIC

Patti G. Grota, PhD, RN, CNS-M-S, CIC, has been active in infection prevention and patient safety for more than 20 years. From 1988 to 2012, Dr. Grota worked in infection control in the South Texas Veterans Healthcare System Infection Control in San Antonio and Kerrville, Texas, and served as deputy chief of the program. She is currently an Assistant Professor of Nursing at Schreiner University in Kerrville, Texas. In addition, she is a member of the Association for Professionals in Infection Control and Epidemiology (APIC) and has served as the President of APIC Chapter 71, San Antonio, Texas.

Dr. Grota has published numerous manuscripts and abstracts and has lectured across the country on topics related to infection prevention and other healthcare-associated adverse events. She was awarded the APIC 2011 New Investigator Award at the 38th Annual Educational Conference and International Meeting for her research in patient factors associated with adverse events of hospitalized veterans in infection control isolation.

Dr. Grota received a Bachelor of Science in Nursing from Oklahoma Baptist University, Shawnee, Oklahoma, in 1976; a Master of Science in Nursing in 1981 from Oklahoma University Health Science Center; and a PhD in Nursing in 2010 from the University of Texas Health Science Center, San Antonio, Texas.
ABSTRACT

Although infection prevention traditionally has approached the problem of resistance primarily from the aspect of preventing transmission, more needs to be done to control how antimicrobials are commonly used. Antimicrobial use is the main selective pressure responsible for the increasing drug resistance seen in hospitals. Patients come to possess a resistant pathogen by either having their bacteria acquire a gene that codes for resistance or by transmitting bacteria that already have the resistance gene in place. The former takes days to weeks to develop, whereas the latter merely requires a handshake. To have an impact on antimicrobial use so as to reduce resistance, infection preventionists need a working knowledge of available antimicrobials, principles for their appropriate use, the mechanisms by which these drugs inhibit microbial growth, and the mechanisms by which microorganisms develop resistance. In addition, infection preventionists need to understand promising new strategies to improve antimicrobial use and how members of the infection prevention community can become more involved.

KEY CONCEPTS

- Although infection prevention traditionally has approached the problem of resistance primarily from the aspect of preventing transmission, more needs to be done to control how antimicrobials are commonly used.
- Antimicrobial stewardship is the best investment for preventing the proliferation of multidrug-resistant pathogens and the adverse events associated with the drugs used to treat such pathogens.
- An antibiogram is a useful tool for infection preventionists to determine the status of strategies in place to reduce multidrug-resistant pathogens.
- A multidisciplinary approach involving infection preventionists; the departments of infectious diseases, microbiology, and pharmacy; and others is necessary to confront antimicrobial resistance issues in healthcare settings.

BACKGROUND

Epidemiological forces responsible for clinically important types of resistance include (1) the selective pressure produced by antimicrobial use and (2) the transmission of resistance between microbes and between or among their human and animal hosts. Although most resistance can be traced to the human behaviors that lie behind these forces, the development and spread of resistance also are greatly affected by certain microbial characteristics, such as the ease by which an organism can develop or acquire resistance traits. Infection prevention, by its very nature, traditionally has been concerned with preventing the transmission of resistant organisms between human hosts in the healthcare setting. This chapter discusses available human antimicrobial agents, how they are used, antimicrobial resistance, and the management of antimicrobial use as a means to control resistance.

This chapter reviews all major antimicrobial categories with special mention of agents that have been released since the last edition of this book. Characteristics and indications for use particularly for drugs commonly used among inpatients, the determination and interpretation of antimicrobial susceptibility test results, and various factors influencing successful antimicrobial therapy are reviewed. The chapter also reviews microbial mechanisms responsible for antimicrobial resistance and methods to monitor and improve antimicrobial use.

BASIC PRINCIPLES

Characteristics of Antimicrobial Agents

Definition

An antimicrobial is a substance that inhibits or kills microbes (viruses, bacteria, fungi, parasites), whereas an antibiotic is a type of antimicrobial that is synthesized by a living microorganism, usually a fungus. Trimethoprim is technically an antimicrobial but not an antibiotic because a microorganism does not synthesize trimethoprim. Many newly marketed agents are chemically modified from products synthesized by a microorganism.

Administration

Most antimicrobials are administered by intravenous (IV) or oral routes. Less common routes of administration include intraocular, rectal, topical, intrathecal, intraventricular, inhalation, intraperitoneal, surgically implanted antimicrobial devices (e.g., orthopedic hardware or beads), and antimicrobial-coated devices (e.g., endotracheal tubes or urinary catheters).
Mechanisms of Action

Antimicrobials may be bactericidal or fungicidal if they actively kill organisms, or they may be bacteriostatic or fungistatic if they merely arrest the growth of organisms and assist the host’s immune system in clearing the infection. Whether a drug exerts “-cidal” versus “-static” activity can depend on the concentration to which an organism is exposed, but for most drugs the safely achieved concentrations in the human body are limited to a narrow enough range that this distinction is determined more by the underlying mechanism by which the drug inhibits microbial growth.

There are several mechanisms by which antimicrobials act on microorganisms (Table 26-1). All β-lactam drugs (e.g., penicillins, cephalosporins, monobactams, and carbapenems; the glycopeptide vancomycin; and the echinocandins (e.g., caspofungin) inhibit cell wall synthesis. Cell membrane inhibitors include daptomycin, colistimethate, and the imidazole antifungal agents, such as fluconazole, which inhibits an enzyme responsible for a crucial component of the cell membrane. Aminoglycosides (e.g., gentamicin and tobramycin), macrolides (e.g., azithromycin), tetracyclines, and the oxazolidinone, linezolid, all inhibit protein synthesis in the bacterial ribosome. Another mechanism inhibits the production of metabolites essential for cell function (e.g., trimethoprim-sulfamethoxazole and ethambutol). Finally, several drugs, including the fluoroquinolones (e.g., ciprofloxacin, levofloxacin, and moxifloxacin), the antifungal flucytosine, and many of the antivirals (e.g., acyclovir) inhibit nucleic acid synthesis.

Pharmacodynamic Factors

The effectiveness of antimicrobials can be optimized by understanding what effect varying the concentration of a drug over time in relation to the minimal inhibitory concentration (MIC) has on eliminating infection from the human body. The MIC is the lowest concentration of drug that still can inhibit microbial growth. The logical assumption would be that for all drugs you have on eliminating infection from the human body.

In order to explain why this is not the case for every antimicrobial, the concept of half-life should be understood. Half-life is a term used to quantify how long the body takes to metabolize half of a drug, an antimicrobial in this case. Drugs such as aminoglycosides and fluoroquinolones are said to manifest concentration-dependent activity. In the case of these drugs, achieving a higher concentration in the blood over a short time is thought to be more effective at eliminating infection than maintaining a lower concentration over a longer period (Figure 26-1). One characteristic of these drugs is that they usually have a prolonged post-antibiotic effect; that is, they continue to suppress microbial growth long after drug concentration has declined. The goal with these drugs is to maximize serum or tissue drug concentrations, which often allows for once-daily dosing.

In contrast, the activity of the β-lactams depends on maintaining drug concentrations in the body above the MIC. Drugs that have such time-dependent (above the MIC) activity are best dosed with lower doses at an increased frequency (Figure 26-2). This understanding has led to drugs such as the natural penicillins and ampicillin being increasingly dosed as a continuous infusion, rather than less frequent dosing, in the management of serious infection. Notice that in Figure 26-1, there is a longer period of time between the end of the half-life and the next dose of the concentration-dependent drug compared to the time-dependent drug in Figure 26-2. Also notice that the concentration curve in Figure 26-1 goes below that MIC level while it stays above the level in Figure 26-2.

Side Effects

Two major types of side effects are allergic and gastrointestinal reactions. Allergic reactions, including those manifested by rash, fever, and rare anaphylaxis, are undesirable effects that may occur with virtually any antimicrobial. Common gastrointestinal disturbances include nausea and vomiting and, because virtually all antimicrobials inhibit microbial growth in the large intestine, diarrhea. Most antibiotic-associated diarrhea is benign and resolves with cessation of the drug, but suppression of the anaerobic bacteria of the colon predisposes to infection with Clostridium difficile. The current C. difficile epidemic strain can cause life-threatening colitis, especially if due to the BI/NAP1/027 strain. Other forms of superinfection resulting from the suppression of normal microbial flora include vaginal candidiasis and oral thrush. Other types of toxicities and their most common manifestations include hepatotoxicity, manifested as elevation of liver enzymes (which is often asymptomatic); myelosuppression, manifested as leukopenia or thrombocytopenia; renal toxicity, manifested as progressive decline in renal function or electrolyte abnormalities; auditory toxicity, manifested as high-frequency hearing loss; vestibular toxicity, manifested as dizziness or vertigo; and central nervous system toxicity, manifested as change in mental status or seizure. Because they often go unrecognized, drug-drug interactions may be particularly prone to cause serious toxicity.

Table 26-1. Major Cellular Sites of Action by Antimicrobial Classes

<table>
<thead>
<tr>
<th>Site of Mechanism of Action</th>
<th>Antimicrobial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cell wall</td>
<td>β-lactam (penicillin)</td>
</tr>
<tr>
<td></td>
<td>Vancomycin</td>
</tr>
<tr>
<td></td>
<td>Echinocandin</td>
</tr>
<tr>
<td>Cell membrane</td>
<td>Cyclic lipopeptide (daptomycin)</td>
</tr>
<tr>
<td></td>
<td>Triazole (fluconazole)</td>
</tr>
<tr>
<td>Ribosome</td>
<td>Macrolide</td>
</tr>
<tr>
<td></td>
<td>Aminoglycoside</td>
</tr>
<tr>
<td></td>
<td>Linezolid</td>
</tr>
<tr>
<td></td>
<td>Tetracycline</td>
</tr>
<tr>
<td>Nucleic acid synthesis</td>
<td>Fluoroquinolones</td>
</tr>
<tr>
<td></td>
<td>Antiviral (acyclovir)</td>
</tr>
<tr>
<td></td>
<td>5-flucytosine</td>
</tr>
<tr>
<td>Metabolic pathway</td>
<td>Trimethoprim-sulfamethoxazole</td>
</tr>
<tr>
<td></td>
<td>Ethambutol</td>
</tr>
</tbody>
</table>
CLASSIFICATION AND REVIEW OF COMMONLY USED DRUGS

The major classification of antimicrobials is based on the broad category of microorganisms against which the drugs possess activity; these include antibacterials (Table 26-2), antivirals (Table 26-3), antifungals (Table 26-4), and antiparasitics.

Antibacterials

Penicillins

The first major antibacterials of the antibiotic era were the natural penicillins, which came into widespread use in the 1940s. All penicillins contain a β-lactam ring, which comprises the core structure of not only the natural and semisynthetic penicillins, but also all cephalosporins, monobactams, and carbapenems. All β-lactam drugs possess bactericidal activity by inhibiting cell wall synthesis. The original penicillin, penicillin G, is a natural product synthesized by the mold Penicillium, which possesses important activity against spirochetes (such as that which causes syphilis). Natural penicillins also have activity against enterococci, most streptococcal species, and anaerobic bacteria found in the human mouth. Natural penicillin remains the drug of choice for the treatment of group A streptococcal pharyngitis and other infections caused by this pathogen, despite more than 50 years of use.

As a result of penicillin G’s lack of activity against Gram-negative bacteria, the aminopenicillins, including ampicillin and amoxicillin, were developed. These drugs possess activity against Gram-negative organisms such as Escherichia coli and Haemophilus influenzae, while retaining all of the Gram-positive and anaerobic activity of the natural penicillins. In re-
response to the rapid spread of penicillin-resistant staphylococci throughout the United States in the 1950s, penicillinase-resistant penicillins were developed. The first of these, methicillin, was released in 1962 and now has been largely replaced by other penicillinase-resistant penicillins with less toxicity, such as nafcillin and oxacillin (IV and dicloxacillin (oral). To combat other penicillinase-resistant penicillins with less toxicity, such as nafcillin and oxacillin (IV and dicloxacillin (oral). To combat the rising incidence of *Pseudomonas* infections in the late 1960s and 1970s, penicillins with antipseudomonal activity were developed, including piperacillin. Then, β-lactamase inhibitors were added to existing penicillins to inhibit bacterial enzymes from lysing the β-lactam chemical ring structure to broaden the activity of the base penicillin for three groups of pathogens: anaerobic bacteria, methicillin-susceptible but penicillin-resistant *Staphylococcus aureus* (MSSA), and Gram-negative bacteria. Currently used β-lactam/β-lactamase inhibitor combinations include amoxicillin-clavulanate, ampicillin-sulbactam, and piperacillin-tazobactam.

### Cephalosporins

Several generations of cephalosporins are available. The first-generation cephalosporins include cefazolin and cephalaxin with activity primarily against Gram-positive bacteria, most *E. coli*, more than half of all *Klebsiella pneumoniae* at most institutions, and most strains of *Proteus mirabilis*. Second-generation drugs include cephalosporins with enhanced activity against *H. influenzae* (e.g., cefotaxime, cefuroxime) and cephalosporins with enhanced antianaerobic activity (e.g., cefoxitin). Both categories of second-generation cephalosporins possess increased activity against enteric Gram-negative bacilli and *Neisseria* spp.

Third-generation cephalosporins (e.g., cefotaxime and ceftriaxone) have enhanced activity against Gram-negative bacilli. They achieve high blood concentrations and penetrate into relatively sequestered body sites, such as the central nervous system. Third-generation cephalosporins are important in the treatment of community-associated meningitis. However, penicillin and cephalosporin resistance among *Streptococcus pneumoniae* is increasing and may limit the usefulness of these drugs as empirical therapy. Although the antipseudomonal third-generation drug cefazidime is important in the treatment of nosocomial meningitis due to Gram-negative bacilli, its use is discouraged because of its association with extended-spectrum β-lactamases. Cefditoren is an oral agent with increased potency against *S. pneumoniae*, including strains that have only intermediate susceptibility to penicillin. Cefdinir has the benefits of being taken only once daily, having an oral suspension, and a similar spectrum of activity compared to other agents in the same class.

Cefepime, a fourth-generation cephalosporin, has broad-spectrum activity against Gram-negative bacteria, including *Pseudo-
monas spp., and Gram-positive bacteria. It is recommended by the Infectious Diseases Society of America for use in patients with neutropenia. However, cefepime covers neither methicillin-resistant \( S. \) aureus (MRSA) nor the anaerobic bacteria responsible for many lung, abdominal, and soft tissue infections. A review by the U.S. Food and Drug Administration (FDA) determined that data do not indicate a higher risk of death with cefepime.\(^3\) Ceftriaxone, the fifth-generation cephalosporin, has activity against MRSA and penicillin-resistant \( S. \) pneumoniae, \( P. \) aeruginosa, and Enterococci. It is intended for use in community-associated pneumonia and skin and soft tissue infections. Both cefepime and ceftriaxone are intravenous antimicrobials.

Miscellaneous \( \beta \)-Lactams

There are two additional classes of \( \beta \)-lactam drugs: monobactams and carbapenems. Aztreonam is the only available monobactam and is unique among the \( \beta \)-lactam drugs in possessing a spectrum of antimicrobial activity limited only to aerobic, Gram-negative bacilli, including \( P. \) aeruginosa. It also is unique in that there is no allergic cross-reactivity between it and other \( \beta \)-lactam drugs, meaning that patients with a history of even serious reactions to penicillins or cephalosporins may be given aztreonam safely. The carbapenems imipenem, meropenem, and doripenem are broad-spectrum agents with significant activity against a wide range of Gram-negative bacilli, including \( Pseudomonas \), and are potent drugs in the treatment of serious infections involving anaerobic bacteria (e.g., intra-abdominal infections with sepsis). They possess activity against streptococci and staphylococci except for MRSA. Ertapenem has a spectrum of activity similar to that of other carbapenems except that it does not cover resistant Gram-negative bacilli, such as \( P. \) aeruginosa or \( Acinetobacter \) spp.

**Fluoroquinolones**

Ciprofloxacin was the first highly potent fluoroquinolone; it still is used widely for the treatment of infections caused primarily by Gram-negative bacilli, including \( P. \) aeruginosa. Fluoroquinolones possess bactericidal activity by inhibiting the bacteria’s DNA gyrase enzyme responsible for unwinding the chromosome during replication and cell division. Most of the available fluoroquinolones are limited in their activity against staphylococci and anaerobes, and ciprofloxacin has limited activity against streptococci. Levofloxacin and moxifloxacin were developed primarily for increased activity against \( S. \) pneumoniae for their use in the treatment of community-associated pneumonia. They also have important coverage against atypical pathogens such as legionella—a pathogen that may be acquired from a water source in or out of a hospital. In addition, levofloxacin covers \( P. \) aeruginosa (although resistance is increasing), whereas moxifloxacin covers anaerobic bacteria.

**Macrolides, Lincosamides, and Streptogramins**

Azithromycin and clarithromycin have activity against Gram-positive bacteria and the atypical bacteria that cause pneumonia, such as \( Legionella \), \( Mycoplasma \), and \( Chlamydia \) spp. The macrolides and the closely related lincosamides and streptogramins (dalfopristin/quinupristin) inhibit 50S protein synthesis in the bacteria’s ribosome. Because they are bacteriostatic and possess a limited spectrum of activity, macrolides are used most commonly to treat less serious community-associated infections. In addition to the treatment of upper and lower respiratory tract infections, macrolides (excluding erythromycin) have unique indications for the treatment of \( Helicobacter pylori \)-induced gastric and duodenal ulcers and infections due to nontuberculous mycobacteria.

Clindamycin is the principal lincosamide currently in use in the United States. Because clindamycin possesses activity against aerobic Gram-positive bacteria and anaerobic Gram-positive and Gram-negative bacteria, it historically has been used in the treatment of aspiration pneumonia and intra-abdominal infections. Its use has increased since the epidemic of community-associated MRSA strains, which commonly cause skin and soft tissue infections. Due to the possibility of treatment failures related to clindamycin-inducible resistance in some staphylococcal strains, a D-test should be performed on staphylococcal isolates to ensure that the drug will be effective. Quinupristin and dalfopristin, a synergistic combination of two streptogramins, was approved only for the treatment of infections caused by vancomycin-resistant \( Enterococcus \) \( faecium \). It also has activity against MRSA but is generally not used in such cases today.

**Aminoglycosides**

Aminoglycosides, such as gentamicin, tobramycin, and amikacin, have long been used in combination with other drugs against difficult-to-treat, Gram-positive and Gram-negative infections. Although they act at the site of the bacterial ribosome, aminoglycosides are bactericidal against most aerobic Gram-negative bacteria. Because of the risk of serious renal toxicity and ototoxicity associated with their use and the fact that they do not have good levels of activity at some sites of infection, use of aminoglycosides now is limited at many centers to only serious or multidrug-resistant, Gram-negative infections. In addition, either gentamicin or another aminoglycoside, streptomycin, used in conjunction with penicillins or vancomycin is needed to achieve cure in the treatment of endocarditis due to susceptible \( Enterococcus \) spp.

Miscellaneous Agents

Vancomycin is a glycopeptide that inhibits cell wall and cell membrane synthesis and is bactericidal against \( Streptococcus \), \( Enterococcus \), and \( Staphylococcus \) spp. It has been a commonly used antimicrobial in U.S. hospitals for MRSA infections for 20 years but is being used less as newer drugs for enterococci and \( S. \) aureus are available. Resistance emerged in the late 1980s among enterococci and in the late 1990s among \( S. \) aureus. The new MICs for vancomycin against \( S. \) aureus are sensitive \( \leq 2 \), glycopeptide-intermediate \( S. \) aureus (GISA) 4 to 8, and vancomycin-resistant \( S. \) aureus (VRSA) \( \geq 16 \).
Daptomycin, a lipopeptide, disrupts the cell membrane and has activity against Gram-positive cocci similar to vancomycin. It has favorable activity in the treatment of skin and soft tissue infections and right-sided endocarditis. However, daptomycin is not reliable for the treatment of primary pneumonia. Studies are in progress for high-dose use.

A new class of compounds, the oxazolidinediones, was developed mainly to address the growing concern over emerging vancomycin resistance. Currently, linezolid is the only available oxazolidinedione; it inhibits protein synthesis and is considered bacteriostatic against Gram-positive organisms. It is indicated principally in the treatment of infections caused by vancomycin-resistant enterococci and MRSA. It has nearly 100 percent bioavailability; therefore, it may be given orally. Monitoring for thrombocytopenia should occur with long treatment durations (> 2 weeks), and caution should be advised if a patient is taking a monoamine oxidase inhibitor or selective serotonin reuptake inhibitor to avoid precipitating the serotonin syndrome.

Polymyxin is a class of antibiotic that was used in the 1960s and 1970s for Gram-negative infections, especially pneumonia, but was abandoned because of its association with renal toxicity. The two forms available are colistin sulfate and colistimethate sodium. Physicians are using polymyxin again because of the emergence of multidrug-resistant Gram-negative infections, such as P. aeruginosa and Acinetobacter baumannii, which are resistant to all other available agents, including carbapenems and aminoglycosides.

Trimethoprim-sulfamethoxazole is a synergistic combination of drugs that together exhibit a bactericidal effect by inhibiting bacterial folate synthesis, an important metabolic pathway. Current clinical use includes the treatment of Pneumocystis jiroveci pneumonia (PCP), infections due to Nocardia spp., and infections involving Stenotrophomonas maltophilia, a multidrug-resistant, Gram-negative nosocomial pathogen. In addition, this drug may be used in its oral form to treat the epidemic of unique strains of MRSA that cause community-associated skin and soft tissue infections, but caution should be used because the drug has been associated with acute kidney disease.4

Rifampin, a rifampicin, is likely familiar to the infection preventionist because it is used as prophylaxis in significant exposures to patients with meningitis due to Neisseria meningitidis. Rifampin also has activity against most MRSA. However, when used alone, resistance often develops quickly due to point mutations in the gene encoding the bacterial RNA polymerase, where rifampicins exert their effect on bacterial growth and survival. Rifampin typically is used as adjunctive therapy for MRSA infection in a patient with an infected prosthetic device or mechanical valve. Rifampin and rifabutin are used in combination with other agents in the treatment of latent or active disease due to M. tuberculosis. Rifaximin is used in the treatment of C. difficile colitis.

Metronidazole is the only nitromidazole currently in use in the United States. It is virtually unsurpassed for its activity in treating anaerobic infection. Because the active drug precursor requires conversion into its active form by an enzyme found only in anaerobic bacteria, metronidazole has no activity against aerobic bacteria. It usually is used as part of combination therapy to treat bacterial infection. Exceptions include the treatment of colitis due to C. difficile. Additional, unique indications for metronidazole include parasitic infections, such as vaginitis caused by Trichomonas vaginalis or intestinal infections due to Entamoeba histolytica or Giardia lamblia.

No discussion of antibacterials would be complete without mention of topical and orally nonabsorbable antimicrobials used for treating superficial infections as prophylaxis against infection under certain circumstances, and for eradicating colonization. A wide variety of drugs have been used for this purpose, including bacitracin, neomycin, polymyxin B, mupirocin, and fusidic acid. Among these agents, mupirocin is of special interest to infection preventionists. This agent, when applied topically to the anterior nares, is part of a regimen for decolonization with MRSA. That process is described in Chapter 93 Staphylococci.

Antivirals

Antivirals are available for many common and life-threatening viruses. Acyclovir was the first widely used antiviral drug, owing to its infrequent toxicity and activity against a common family of human viruses, the Herpesviridae. Although acyclovir is available in an oral form, it is poorly absorbed; the derivatives of acyclovir, valacyclovir and famciclovir, overcome this problem and for most indications are the preferred oral agents. All of these agents are active against herpes simplex viruses (type I and II). Most patients infected with herpesviruses are managed as outpatients; however, severe infections in immunocompromised patients often require inpatient treatment. Likewise, encephalitis due to herpes simplex requires inpatient, IV acyclovir therapy.

Although acyclovir and related agents are less active against varicella-zoster virus, they retain meaningful activity against this virus, which is responsible for chickenpox as a manifestation of primary infection and shingles, or herpes zoster, as a manifestation of secondary or recurrent infection. Most cases of chickenpox in immunocompetent individuals do not require inpatient therapy; however, treatment of patients with herpes zoster using acyclovir or one of its derivatives may reduce the commonly seen complication of postherpetic neuralgia.

Acyclovir and related drugs possess some activity against the cause of infectious mononucleosis, Epstein-Barr virus, but this infection does not routinely require antiviral therapy in immunocompetent patients. In contrast, because these agents are active agent precursors that are converted into their active form by a viral thymidine kinase enzyme, acyclovir and its derivatives have little or no activity against cytomegalovirus (CMV), which commonly infects immunocompromised patients but lacks a thymidine kinase. Ganciclovir and valganciclovir are the first-line drugs used to treat most CMV...
infections. IV ganciclovir is the drug of choice for serious life-threatening pneumonitis in solid organ and bone marrow transplant patients. Ganciclovir and valganciclovir are associated with significant bone marrow toxicity. In patients who cannot tolerate or fail to have a response to ganciclovir, foscarnet may be used as second-line therapy to treat serious CMV infections.

Other antivirals include cidofovir with activity against herpesviruses 6 and 8, Epstein-Barr virus, and a variety of other DNA viruses, including papillomavirus, polyomavirus, poxvirus, and adenoovirus. Anti-influenza drugs include amantadine and rimantadine for influenza A and zanamivir and oseltamivir (neuraminidase inhibitors) for influenza A and B. Ribavirin covers a wide range of RNA and DNA viruses and now has as its main use the treatment of Hepatitis C (when used in combination with interferon) in addition to its long-standing use in treating children with respiratory syncytial virus. Interferons stimulate the patient’s own immune system to control and in some cases clear Hepatitis B, Hepatitis C, herpesvirus, and papillomavirus. Although not in common clinical use for this purpose, when given prophylactically, interferons also can protect patients from infection with respiratory viruses, including respiratory syncytial virus (RSV), rhinovirus, and coronavirus.

Antiretrovirals revolutionized the care of patients infected with HIV with the advent of antiretroviral therapy (ART). ART consists of combinations of various drugs that act in combination to suppress viral replication effectively, the therapy has improved survival markedly. Although the focus of ART is long-term therapy among outpatients, these drugs are now commonly used for postexposure prophylaxis of healthcare personnel exposed to HIV. The major categories of antiretrovirals (and several representative agents) include the entry inhibitor, maraviroc; the fusion inhibitor, enfuvirtide; nucleoside or nucleotide reverse transcriptase inhibitors (NRTI; e.g., emtricitabine, lamivudine, tenofovir, zidovudine); non-nucleoside reverse transcriptase inhibitors (NNRTI; efavirenz, nevirapine, etravirine, rilpivirine); protease inhibitors (PIs; e.g., atazanavir, darunavir ritonavir); and integrase inhibitor. Combinations of these drugs make up the typical postexposure prophylaxis regimen.

**Antifungals**

The availability of highly active imidazoles, such as fluconazole and itraconazole, has had a major impact on the treatment of some human fungal infections, such as candidiasis. Fungal sensitivities are now available to ensure treatment is appropriate and to alert the infection preventionist when a resistant strain is increasing in the hospital. Attention should be given when instructing patients to take imidazoles because absorption is better during certain times. The newer triazoles, voriconazole and posaconazole, are used for invasive aspergillosis and disseminated candidiasis, and voriconazole has a unique indication for serious fungal infections caused by *Scedosporium apiospermum*. The echinocandins are a class of compounds that inhibit the synthesis of glucan, an essential component of the fungal cell wall. Among the echinocandins, caspofungin is indicated for refractory aspergillosis, candidiasis, and some invasive candidal infections. At this time, anidulafungin and micafungin are primarily used for invasive candidal infections, although they also cover *Aspergillus*.

Amphotericin B deoxycholate, a suspension of a polyene compound that weakens the fungal cell membrane through interaction with ergosterol, has largely been replaced by the antifungals already discussed because they are efficacious without the renal and hepatic side effects. The decrease in side effects is significant, even in comparison with the lipid formulations of amphotericin B (Amphotec, Abelcet, and AmBisome). Should they need to be used, they are still effective against cryptococcosis, histoplasmosis, invasive aspergillosis, and other serious infections caused by yeasts or molds, with the exception of *S. apiospermum*. Flucytosine is a nucleoside analogue that is additive with amphotericin in the treatment of infections due to *Candida* spp. and *Cryptococcus neoformans*.

**Antiparasitics**

Although parasitic infections constitute many of the most common infections in the world, they occur relatively infrequently in the United States. Drugs such as chloroquine, primaquine, quinine, mefloquine, and doxycycline are used for the treatment or prophylaxis of malaria, a protozoan infection associated with significant morbidity and mortality in endemic regions. Schistosomiasis, caused by a platyhelminth, is treated with praziquantel. The treatment of nematodes (roundworms) includes ivermectin and albendazole. Some antiparasitics are only available in the United States from the Centers for Disease Control and Prevention (CDC).

**INDICATIONS FOR ANTIMICROBIAL USE**

**Pathogen-directed Therapy**

Appropriate reasons for antimicrobial use are categorized as pathogen directed, empirical, or prophylactic. Pathogen-directed therapy describes antimicrobial use when the microbial pathogen has been determined based on the results of traditional culture, serology, or other methods, such as polymerase chain reactions (PCR), to detect distinct nucleic acids of the microbial pathogen. If a culture has been used to recover the offending microbe and that microbe is a bacterium or yeast, antimicrobial susceptibility results may be made available. In pathogen-directed therapy, the use of the narrowest spectrum antimicrobial is believed to reduce the emergence of antimicrobial resistance and superinfection. Minimizing the cost of therapy also is important whenever equivalent alternatives are available.

Although therapy based on a positive nucleic acid amplification (e.g., PCR) test or other nonculture diagnostic test
is considered pathogen directed, susceptibility results are not available to tailor therapy. To overcome this problem, a culture sometimes is performed in tandem to confirm the nonculture test result and provide an organism for future susceptibility testing. Whenever a nucleic acid amplification test is performed on a sputum sample for tuberculosis, a smear and culture also should be performed for confirmation and susceptibility testing. However, the nucleic acid amplification test result may be able to provide a much more rapid answer as to whether the patient likely has tuberculosis, rather than waiting the full 4 to 6 weeks for Mycobacterium tuberculosis culture results.

In other instances, the nonculture result directs therapy against a pathogen with a predictable susceptibility pattern. A nucleic acid amplification test result that is positive in the case of a sexually transmitted disease (STD) caused by gonorrhea or Chlamydia routinely triggers therapy that has been recommended by consensus public health guidelines, but these sexually transmitted diseases, as well as C. difficile colitis, PCP, and other infections are treated immediately on the basis of a consistent clinical picture.

Empirical Therapy

When no definitive information about a causative pathogen is available (although Gram stain can be highly suggestive), therapy is said to be empirical. Typically, hospitalized patients are sufficiently ill to warrant treatment before culture and sensitivity results are available, and therapy while the results of cultures are pending may represent most empirical therapy. Especially in hospitalized patients, appropriate cultures, usually including more than one blood culture, should be collected before the initiation of therapy. The site of infection determined clinically (e.g., lung, urinary tract) and host factors (e.g., HIV, organ transplant patient) give an indication of likely pathogens and should shape the decision regarding empirical therapy. Empirical therapy, compared with pathogen-directed therapy, is broader in spectrum due to uncertainty about the causative agent.

Prophylaxis

Antimicrobial use that is designed to prevent infection rather than treat known or suspected infection is deemed prophylactic. Surgical antimicrobial prophylaxis is the most common type of prophylaxis and it is indicated for surgical procedures in which the risk of wound infection is high enough to show significant benefit of prophylaxis. This is exemplified best in operations involving placement of a prosthetic device, in which an infection would be a major cause of morbidity or mortality (e.g., prosthetic heart valve placement), and operations in patients with severe immunosuppression.

Basic principles of antimicrobial prophylaxis in surgery should be recognized. The antimicrobial spectrum of the drug chosen should be appropriate for the organisms most likely to cause infection. These are most commonly Staphylococcus spp. or Streptococcus spp., even in abdominal surgeries, in which other organisms predominate in the bowel flora. Adequate tissue levels of the antimicrobial, usually a first-generation cephalosporin, should be present throughout the operative procedure from the time of first incision onward. The duration of prophylactic antimicrobial use should be as short as necessary to minimize the emergence of resistant organisms, reduce the incidence of side effects, and reduce cost; this translates in most cases to a single preoperative dose and occasionally an additional dose or two if surgery duration is prolonged. In general, any time the skin or mucosa is incised, prophylaxis should be considered, whether the wound is clean, clean-contaminated, contaminated, or dirty. Surgical prophylaxis should also be considered for patients whose physical status, as measured by the American Association of Anesthesiologists (ASA) score, is three or more out of five—meaning severe systemic disease is present. Other unique medical conditions requiring antimicrobial prophylaxis include the prevention of endocarditis in patients with high-risk valvular lesions, spontaneous bacterial peritonitis in patients with ascites, and malaria in patients traveling to endemic areas. Certain types of prophylaxis are given immediately after exposure to a high-risk pathogen that causes disease, such as meningococcal meningitis and HIV.

STRATEGIES TO PREDICT AND IMPROVE PATIENT OUTCOME

Factors That Affect Outcome

Five major factors contribute to successful antimicrobial therapy: (1) prompt institution of an appropriate antimicrobial; (2) the “bug” factor, related to the virulence and susceptibility of the infecting organism; (3) the “drug” factor, related to the activity of the antimicrobial at a particular site of infection; (4) the “host” factor, related to the underlying condition and immunocompetence of the patient; and (5) the “site” factor, related to the fact that infections at certain body sites (e.g., meninges, heart valves) are inherently more difficult to treat for a variety of reasons. Although one usually can have an impact only on the first factor, an awareness of each of the remaining four is essential for choosing the most appropriate antimicrobial. Selection of an antimicrobial agent that is highly active according to in vitro susceptibility test results is crucial; however, under some circumstances, this intervention alone is of limited value. In the management of infected prosthetic material, the removal of the prosthesis rather than the result of in vitro susceptibility testing would be most predictive of patient outcome. Likewise, the outcome of a patient with an abscess or intra-abdominal infection in most cases is affected much more by surgery or percutaneous drainage than by antimicrobial therapy.

In addition to choosing the most appropriate antimicrobial, the most appropriate dose and route of administration must be selected to improve outcome. The dose must be high enough to be therapeutic (i.e., sufficient to inhibit or kill
organism at the site of infection) but low enough to minimize toxicity. In certain circumstances, host factors require modification of the dose. The presence of renal failure requires a dose reduction of antimicrobials excreted primarily by the kidney (e.g., aminoglycosides, fluoroquinolones, trimethoprim, tetracycline, vancomycin, and all β-lactams except nafcillin and ceftriaxone). Likewise, hepatic insufficiency requires a dose reduction of antimicrobials excreted primarily by the liver (e.g., chloramphenicol, clindamycin, doxycycline, macrolides, metronidazole, rifampin, sulfamethoxazole, ceftriaxone, nafcillin). The site of infection also may influence administration of the antibiotic. In central nervous system infections, the antimicrobial dose frequently needs to be increased for a successful outcome, whereas in urinary tract infections, lower antimicrobial doses are appropriate.

The initial administration of antimicrobials to hospitalized patients is usually via the IV route so that therapeutic levels can be achieved quickly and reliably. IV administration in most cases also results in higher blood levels than can be achieved via the oral route. The exception is for drugs that are exceptionally well absorbed by the gastrointestinal tract, such as fluconazole, the fluoroquinolones, linezolid, and metronidazole. However, even in the case of drugs that are not as well absorbed, sufficient levels usually can be achieved via oral administration so that infected, hospitalized patients can be switched rapidly from IV to oral antimicrobials after an initial response to therapy. This is termed switch therapy and has been studied most widely as a means to reduce length of hospitalization and overall healthcare costs for patients with community-associated pneumonia.8

Antimicrobials interact in a variety of ways when coadministered. Some antimicrobials directly inactivate others; for example, piperacillin/tazobactam and aminoglycosides inactivate each other when added to the same IV bottle. Antagonism, which is distinct from inactivation, describes the condition of two coadministered antimicrobials that become less effective than either one administered alone. Tetracycline, a bacteriostatic drug, may interfere with the action of penicillin, a bactericidal and cell wall synthesis inhibitor, by preventing cell growth and division. Synergy describes the condition when two coadministered antimicrobials are more effective than what the simple addition of the two agents would predict. In the treatment of endocarditis due to Enterococcus spp., in which bactericidal activity is necessary to achieve cure, this can be provided by the synergistic combination of a protein inhibitory agent, such as an aminoglycoside, with a cell wall-active agent, such as penicillin or vancomycin.

**Description of Antibiogram**

Although the responsibility of publishing an antibiogram traditionally has been assumed by the clinical laboratory, periodic preparation and dissemination of institutional resistance patterns provide infection prevention personnel insights into what antimicrobial classes are most used and potentially misused. Infection preventionists should be involved in the preparation of the antibiogram and aware that there are guidelines regarding this issue available from the Clinical and Laboratory Standards Institute (CLSI).9

An antibiogram simplifies multiple patients’ antimicrobial sensitivity information at an institution into a single number for pathogens of interest in an effort to monitor trends emerging in drug resistance. Antibiograms help answer questions in two main areas: clinical care (what antimicrobial would be best to use in this hospital for this pathogen?), and infection prevention strategies (has the resistance of this pathogen to this antimicrobial changed in this hospital to warrant augmenting or diminishing our infection prevention interventions?). With resistance increasing, limited resources, and clinical questions pending, antibiograms are a useful tool in medicine.

The technical details of generating an antibiogram are contained in the CLSI document M39-A2, whereas the following is a brief, pertinent summary for the infection preventionist.9,10 An antibiogram report should be presented at least annually. Data should be analyzed when at least 30 isolates are tested for a given pathogen, and only the first isolate should be included from patients with multiple positive cultures, regardless of the body fluid tested or the antimicrobial susceptibility pattern. Incidentally, because an antibiogram considers only the first isolate, infection preventionists should know that the microbiology laboratory is the place to inquire about the number of any multidrug-resistant isolate of interest. At least 30 diagnostic, not surveillance, isolates of a species should be included in an analysis to provide a meaningful number, and only then for drugs that are routinely tested. Antibiograms should report the proportion of susceptible isolates, not isolates with intermediate susceptibility. However, penicillin-intermediate susceptibility is of interest for S. pneumoniae. For S. pneumoniae, the proportion susceptible to cefotaxime or ceftriaxone using both the meningitis and nonmeningitis breakpoints should also be included. When calculating the proportion of susceptibility for S. aureus, include the subset for MRSA.

An antibiogram should include a table with pathogens with the total number of isolates listed against antimicrobials (Figure 26-3). The figure reveals, for example, that there were 48 isolates of S. pneumoniae with 81 percent sensitive to tetracycline. The value for penicillin and S. pneumoniae has two values, one each for the meningitis and nonmeningitis breakpoints. The 2009 CLSI document M39-A3 emphasizes that an antibiogram may be generated for specific units in an institution; note that Figure 26-3 is only for patients outside of the intensive care unit.9 It will also highlight that antibiograms could underestimate the activities of drugs for multidrug-resistant strains in specific units. For example, if Klebsiella strains are analyzed together, the activities of drugs against non-Klebsiella pneumoniae carbapenemase producers will be underestimated.
ANTIMICROBIAL RESISTANCE

Antimicrobial resistance is an important global public health problem that is particularly acute among hospitalized patients. The detrimental impact of antimicrobial resistance on the treatment outcome of healthcare-associated infections (HAIs) has been increasingly documented not only in terms of increased morbidity, but also as a contribution to increased mortality. In addition, resistance contributes significantly to increased healthcare costs. The excess U.S. healthcare costs attributed to just six common forms of resistance in nosocomial pathogens has been estimated to exceed $13.3 million.11

Antimicrobial Susceptibility Testing

In vitro (laboratory) susceptibility testing provides important predictive information of whether an infection is likely to respond to a particular antimicrobial in vivo (patient). The most commonly used test method includes the microtiter broth dilution systems using trays of small-volume wells consisting of various concentrations of antibiotic read via an automated, commercial instrument.12 Other test methods include agar disk diffusion (Kirby-Bauer) and the antimicrobial gradient diffusion method (E-test or D-test), in which a reagent strip consisting of a gradient of concentrations in the medium.

Each of the above-mentioned test methods is performed and interpreted using standardized criteria according to published recommendations of the CLSI.13 Although disk diffusion test results are expressed qualitatively, broth, agar, and E-test results may be expressed quantitatively as an MIC. Although these systems consist of a broth dilution test, manufacturers commonly limit the number of concentrations tested to only

Figure 26-3. Sample of an antibiogram for patients from non-ICU locations within the University of Louisville Hospital, 2007.
breakpoint concentrations that separate susceptibility categories. For example, breakpoint concentrations for ciprofloxacin tested against *E. coli* would be 1 μg/mL (a low concentration of the drug at which there is inhibition of growth, and thus the *E. coli* is considered susceptible); and a breakpoint of 4 μg/mL (a high concentration of the drug at which there is growth, and thus the *E. coli* is considered resistant). If growth is present at 1 μg/mL but inhibited at 4 μg/mL, the ciprofloxacin is considered intermediate.

Clinical laboratories typically report results using the recommended qualitative result categories of susceptible, intermediate-susceptible, and resistant based on the breakpoints set by CLSI. *Susceptible* means that the drug is likely to be effective for the treatment of infection using a standard dosage. *Intermediate-susceptible* means that the drug is likely to be effective only at body sites where it is physiologically concentrated (e.g., the urine for most drugs) or at other body sites if higher-than-usual dosing regimens are used. *Resistant* means that the drug is unlikely to be effective for the treatment of infection unless predictably toxic dosages are used. Laboratories should consider not including MIC or breakpoint concentrations without interpretation provided because they may be misinterpreted.

**Mechanisms**

Major mechanisms of antimicrobial resistance include drug inactivation and alteration in target site, decreased permeability or efflux, and bypass of a metabolic pathway (Figure 26-4). Drug inactivation occurs when a bacterium produces an enzyme that can destroy or inactivate the antimicrobial; bacteria may produce β-lactamase enzymes that destroy penicillins and cephalosporins. Alternatively, drug receptor or target sites may undergo alteration, as observed in MRSA when the penicillin binding protein (PBP) is altered to PBP2a, coded for by the better known *mecA* gene. Changes in drug permeability or an efflux of drug may be observed, as in the case of *P. aeruginosa* that has developed resistance to the carbapenems. Finally, bacteria may develop alternative metabolic pathways to bypass the pathway that was inhibited by the antimicrobial; resistance to trimethoprim-sulfamethoxazole commonly occurs in this manner.

Resistance develops in microorganisms as a result of either point mutations in existing genes or the acquisition of new genes. Point mutations are random errors that occur during DNA replication, resulting in the substitution of one base pair for another, which may result in the substitution of one amino acid for another in a protein structure or enzyme. These mutations occur infrequently at the correct locations of the bacterial genome necessary to cause resistance ($10^7$ to $10^{12}$ per generation); when point mutations are responsible for resistance, it usually is because they have a slight structural change in a drug-receptor or target site. However, because most forms of antimicrobial resistance require complex structural or enzymatic changes, most forms of resistance result from newly acquired genes.

**Transmission**

Point mutations that result in resistance usually occur in the chromosome of the microorganism and are passed on only to daughter cells via cell division; however, mobile genetic elements also exist that can promote the transmission of genes between strains. These include plasmids and transposons. Plasmids consist of a circular segment of extrachromosomal DNA that can replicate itself. A transposon is a segment of DNA that can insert itself in the chromosome and be transmitted between cells via a plasmid or even a virus. Together these mobile genetic elements or "jumping genes" are known as resistance
**Factors (R factors).** Resistance that is carried on R factors is potentially more serious than resistance caused by point mutations in the chromosome because resistance can be spread to different strains or even different species of microorganisms. R factors commonly contain multiple genes conferring resistance to several antimicrobials, whereas point mutations generally confer resistance to only one class of antimicrobials.

Certain resistance genes acquired by a microorganism via an R factor may become stably inserted into its chromosome and, similar to a chromosomal point mutation, be passed on to daughter cells via cell division. The transmission of such chromosomal resistance may be distinguished epidemiologically from the transmission of R factors in the hospital. Chromosomal resistance is spread among patients as a single strain or clone, and in this sense the resistance is said to be “clonal,” whereas R factor resistance usually involves multiple strains or clones and is said to be “polyclonal.” Distinguishing a clonal from polyclonal outbreak of resistance in a single species often requires molecular characterization of isolates from several patients. A description of the molecular techniques to perform such characterization in the laboratory is outside the scope of this chapter. See Chapter 93 Staphylococci.

**Examples**

Antimicrobial resistance has been found in hospitals since the advent of penicillin and the discovery of penicillinase-producing *S. aureus* in the 1940s. MRSA first were detected in the early 1960s, shortly after the introduction of methicillin, and aminoglycoside resistance among Gram-negative bacilli first was noted in the 1970s. During the 1970s and 1980s, MRSA spread so widely that vancomycin had to be used increasingly to treat these infections. This set the stage for the development and spread of vancomycin-resistant enterococci (VRE), first in Europe in the late 1980s and then in the United States by the early 1990s. Klevens reported that nearly one in five adults hospitalized with a MRSA infection die.14

The 1990s saw that the spread of fluconazole resistance increased among *Candida* spp. (e.g., *C. krusei*, *C. glabrata*, and occasionally *C. albicans*). During this same time, identification of expanded-spectrum *β*-lactamases (ESBLs) increased in some hospitals. ESBLs are *β*-lactamases found in common Gram-negative bacteria, such as *E. coli* and *K. pneumoniae*, which confer resistance to all *β*-lactam drugs except the carbapenems. The most recent form of antimicrobial resistance that has caused concern includes the *β*-lactamases associated with carbapenem-resistant Enterobacteriaceae (CRE). The media has publicized CRE as a “superbug.” CRE is the group of Gram-negative pathogens that are resistant to most antimicrobials, including carbapenems which have been useful for multidrug-resistant pathogens until now. The resistant enzyme may be encoded within a bacteria’s own DNA chromosome affecting a whole species, or acquired on a transposon or plasmid affecting a strain of a species. One of the worst outbreaks was with a plasmid mediated *Klebsiella pneumoniae* carbapenemase at a National Institutes of Health (NIH) medical facility in Maryland where 11 of 18 patients died. From an infection prevention perspective, patients with ESBL or carbapenemase multidrug-resistant organisms need to be in contact isolation.15

The late 1990s raised concern for vancomycin resistance in MRSA. In 1996, GISA first was reported from Japan16 and then the United States17 where VRSA was described in 2002.18 VRSA resulted from the new acquisition of resistance genes from VRE. Unfortunately, resistance has been reported with linezolid and daptomycin use. Antimicrobial stewardship is critical to preventing antimicrobial prescribing habits that provide an environment conducive to such a resistant pathogen.

**ANTIMICROBIAL STEWARDSHIP**

Strategies other than simply new drug development must be stressed to curb antimicrobial resistance. Healthcare institutions provide care to patients at increased risk of infection who, because they are exposed to antimicrobial selective pressure, are also at risk of colonization or infection by antimicrobial-resistant pathogens. These patients are in close proximity to one another so that resistance is transmitted easily. Just as there has long been understanding of the role of infection prevention in preventing transmission of antimicrobial resistance, there is an increasing awareness of the need to manage antimicrobial use in hospitals more carefully. Antimicrobial stewardship programs are important components of antimicrobial resistant management in healthcare institutions. The Infectious Diseases Society of America (IDSA) has multiple relevant guidelines for this purpose available at http://www.idsociety.org. (See Supplemental Resources, Dellit and colleagues.)

**Surveillance**

The surveillance of antimicrobial resistance is an essential first step in identifying priority areas for managing antimicrobial use from an infection prevention perspective versus a pharmacy or cost-containment perspective. In addition to tracking the proportion of isolates that are resistant (i.e., antibiogram), Infection preventionists should consider tracking the number of patients who are found on routine cultures to be newly colonized or infected with problem areas of resistance, such as MRSA, VRE, or *C. difficile*. The spread of these forms of resistance may be expressed as episodes of newly detected colonization or infection per 100 admissions or 1,000 patient days; this information is crucial for infection prevention efforts aimed at controlling resistance and antimicrobial use quality improvement. Along with these forms of surveillance, vigilance should be maintained by laboratory and infection prevention personnel with regard to the possible emergence of sentinel resistance patterns, such as vancomycin resistance in *S. aureus*.

**Antimicrobial Management Team**

The next step in monitoring and improving antimicrobial use involves antimicrobial auditing. This is accomplished best
through the formation of a multidisciplinary antimicrobial team, the members of which should include, if possible, an infectious diseases physician, clinical pharmacists, and personnel from the clinical laboratory and infection prevention. The mission of such a team usually includes controlling antimicrobial costs and improving patient care and reducing resistance. The infection prevention team member should emphasize the latter goals.

With so many members, it is easier to think of the team as having an administration arm and a clinical arm. The administration arm is responsible for identification of potential problem areas either from resistance patterns or from drug costs and consumption data from the pharmacy. Decisions can be made regarding whether targeted or general audits should be undertaken. In either case, guidelines of acceptable use are needed against which to compare practice; these should be developed at the institutional level based on available national or international consensus guidelines. Consensus guidelines recommending appropriate empirical therapy of common infections now are increasingly accepted as the standard of care. The IDSA Antimicrobial Stewardship guideline outlines evidence-based strategies related to monitoring antimicrobial use. Other general areas where audits can be undertaken include the appropriateness of dosing, whether surgical antimicrobial prophylaxis is used according to the aforementioned described principles, and whether empirical therapy is routinely narrowed to pathogen-directed therapy when culture results become available.

The clinical arm, usually including clinical pharmacist members and infectious diseases physicians and fellows, is responsible for performing audits prospectively or retrospectively. Prospective or “real-time” audits offer the advantage of uncovering additional information regarding why antimicrobials are used and, more importantly, the opportunity to intervene by making recommendations of how to improve antimicrobial use. They also collect and enter data into a database to monitor their interventions over time. The clinical arm of the antimicrobial program is critical for a program’s success because it enforces the policies and antimicrobial guidelines drafted by the administrative arm of the program.

Success of any program depends on improving practice wherever inappropriate antimicrobial use is found. Elements critical for the success of the antimicrobial team will be determined by a local application of the IDSA guidelines, such as having appropriate personnel, dedicated time, appropriate education, and clear goals. Several methods have been used to improve antimicrobial use with an aim of controlling resistance. The first of these methods is intervention, such as computer-assisted drug protocols and feedback of prescribing habits in relation to guidelines. These methods could include the prospective, real-time interventions made by members of an antimicrobial team conducting audits, as discussed earlier. Reports should be a part of feedback, and feedback should be given to prescribers as well as people to whom the prescribers are accountable. For example, a report to the chiefs of medicine and surgery could include lists of the most common infections treated, the most common antimicrobials prescribed in the hospital, and an overall summary of internal medicine and surgeons’ compliance, respectively, with the hospital antimicrobial guidelines. The second method is a paternal approach that restricts access to certain drugs, such as exclusion from the formulary, placement on a list of drugs requiring approval before dispensing, and alternating the use of different classes of antimicrobials to prevent the emergence of resistance (i.e., antibiotic cycling). The third method is an academic approach involving didactic instruction and the promulgation of institutional antimicrobial guidelines among prescribers. As an alternative to formal didactic instruction, education of prescribers has been done by means of written information and face-to-face interactions (i.e., counter-detailing) carried out by clinical pharmacists, nurse practitioners, or physicians. Use of a combination of strategies to improve antimicrobial use has been shown to be more efficacious than use of a single method.

As part of this collaborative approach, some attention should be paid to the influence of the pharmaceutical industry on prescribing. Whatever method is used, as a general rule, interventions to improve antimicrobial use should be implemented in collaboration with the pharmacy and therapeutics and quality improvement committees and members of the hospital administration.

INTERNATIONAL PERSPECTIVE

There are several aspects to understanding antimicrobial use and resistance and how to improve antimicrobial use that require modification to apply to settings outside the United States and North America. Drugs other than those described earlier may be used commonly in the international setting. Certain drugs that have been granted FDA approval are not available overseas and vice versa. In addition, drugs may be used outside the healthcare setting (i.e., in the community or in animal food production) differently and in such a manner that they are more likely to affect resistance in hospitals. For example, the use of avoparcin, a glycopeptide related to vancomycin, has long been used in animal food production in Europe and East Asia but not in the United States and has been linked to VRE found among hospitalized patients in regions where it is used. Likewise, the availability of antimicrobials over-the-counter without a prescription in many developing countries may influence resistance patterns, albeit predominantly in community pathogens.

Another major area to consider is how cultural differences and differences in healthcare financing may influence the effectiveness of measures designed to improve antimicrobial use. In some cultures, the clinical services are hierarchical, and recommendations made by a clinical pharmacist member of the antimicrobial team are much less likely to be followed. Instead, physician-to-physician interaction or interaction among senior physicians and administrators may be necessary to effect a change in prescribing patterns.
ACKNOWLEDGMENTS

The author acknowledges Janet Hindler, MCLS, MT (ASCP), Sr. Specialist in Clinical Microbiology at UCLA Medical Center Los Angeles, California, for her contributions regarding the 2009 CLSI document M39-A3.

REFERENCES


SUPPLEMENTAL RESOURCES
